Company news

Roivant Sciences Ltd. news in 2024

Roivant Sciences Ltd.'s news releases, calls and decks from 2024, newest first.

View company

Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

December 2, 2024

Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

December 2, 2024

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update

November 11, 2024

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

October 28, 2024

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

October 27, 2024

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

September 17, 2024

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

September 9, 2024

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

September 9, 2024

Roivant Provides Update on Graves’ Disease Development Program

September 8, 2024

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

August 7, 2024

Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024

July 24, 2024

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

May 29, 2024

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

May 15, 2024

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

April 1, 2024

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

March 25, 2024

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

February 12, 2024

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

January 29, 2024

Calls in 2024

Decks in 2024